Cite
HARVARD Citation
Kato, A. et al. (2022). Class III β-Tubulin Expression Is of Value in Selecting nab-Paclitaxel and Gemcitabine as First-Line Therapy in Unresectable Pancreatic Cancer. Pancreas. 51 (4), pp. 372-379. [Online].
This is an interim version of our Electronic Legal Deposit Catalogue-eJournals and eBooks while we continue to recover from a cyber-attack.
Kato, A. et al. (2022). Class III β-Tubulin Expression Is of Value in Selecting nab-Paclitaxel and Gemcitabine as First-Line Therapy in Unresectable Pancreatic Cancer. Pancreas. 51 (4), pp. 372-379. [Online].